List of works - Sossana Delimpasi

Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents

scientific article published on 30 May 2011

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.

scientific article

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

scientific article published on 20 August 2015

Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

scientific article published on 01 September 2018

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study

article

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy

scientific article published on 21 December 2011

European perspective on multiple myeloma treatment strategies: update following recent congresses

scientific article

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents

scientific article published on 6 May 2010

Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel anti-myeloma therapies.

scientific article

Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents

scientific article published on 26 January 2014

Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.

scientific article published in July 2012

No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

scientific article published on 20 April 2011

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

scientific article published on 01 November 2020

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma

scientific article published on 20 November 2018

Prognostication of the High-Risk WM Patient

scientific article published on 01 February 2011

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

scientific article published on 13 May 2018

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

scientific article

Virus infection and autoimmunity: is there a cause-and-effect relationship?

scientific article published on 12 August 2013

List of works by Sossana Delimpasi

Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy

European perspective on multiple myeloma treatment strategies: update following recent congresses

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents

Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel anti-myeloma therapies.

Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents

Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.

No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma

Prognostication of the High-Risk WM Patient

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

Virus infection and autoimmunity: is there a cause-and-effect relationship?